Non-Alcoholic Fatty Liver Disease is a looming public health crisis
ILC 2021 Press Conference 25 June - NAFLD / NASH
EASL Studio S4E12 - NAFLD and NASH – moving beyond the liver biopsy – where are we now?
EASL Studio S4E23 - The Conundrum of NASH
EASL Policy Statement on the coexistence of NAFLD and ARLD (Patient Forum 2020)
EASL Studio Policy Dialogues Ep4 - Fatty Liver Disease: The Approaching Tsunami in NCDs
EASL Studio S4E3 - A 360 approach to beat alcohol-related liver disease
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk
EASL Studio - S2 E17 - EASL Haemochromatosis Guidelines 2022
EASL Grand Round Series: Overcoming Steatosis
Multi-society and multi-stakeholder consensus revision of the NAFLD nomenclature: the final results
Webinar: EASL Update - FibroScan Applications in NAFLD-NASH
Crucial updates on Fatty Liver disease - EASL 2023 - steatotic liver disease, MASLD, and MetALD
Highlights from the EASL NAFLD Summit 2022 - EASL STUDIO Season 3 Episode 4 (September 28)
FLF LIVER Webinar Series | Part-One (Highlights from EASL 2020)
EASL Studio S4 Special Edition - A new strategy for liver cancer screening
EASL Patient Forum 2021: Health literacy to empower liver patients and address inequities
EASL Studio - Season 1, Episode 3 - The EASL-Lancet Liver Commission
EASL Grand Round Series: Coagulation and Cirrhosis
EASL Studio - S3E6 - How to improve end-of-life care in liver disease?